Source: Annual Congress 2004 - Lung transplantation: new insights in advanced lung disease and new drug developments - do they impact on selection criteria?



Rating:

Share or cite this content

Citations should be made in the following way:
J. Orens (Baltimore, United States Of America). Lung transplantation for pulmonary hypertension: the impact of new drug therapies. Annual Congress 2004 - Lung transplantation: new insights in advanced lung disease and new drug developments - do they impact on selection criteria?

Member's Comments

No comment yet.

Related content which might interest you: Is sildenafil an effective bridging therapy to lung transplantation for patients with pulmonary hypertension in the setting of lung disease? Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 New issues in lung transplantation for pulmonary hypertension Source: Virtual Congress 2020 – Lung transplantation in the era of new drugs Year: 2020 Impact of pulmonary hypertension after lung transplantation on functional outcome Source: Annual Congress 2010 - Pre-operative evaluation and post-operative problems after lung transplantation Year: 2010 Pulmonary hypertension: new guidelines for therapy Source: Annual Congress 2007 - PG19 - Pulmonary vascular disorders: diagnosis and treatment Year: 2007 Epoprostenol therapy for primary pulmonary hypertension after rejection of a single donor lung Source: Eur Respir J 2003; 21: 192-194 Year: 2003 Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation Source: Eur Respir J 2012; 39: 1520-1533 Year: 2012 Severe pulmonary arterial hypertension: treatment options and the bridge to transplantation Source: Eur Respir Rev 2014; 23: 488-497 Year: 2014 Lung transplantation for pulmonary hypertension Source: Eur Respir Mon 2012; 57: 247-255 Year: 2012 Safety of antifibrotic drugs in idiopathic pulmonary fibrosis patients awaiting lung transplantation Source: International Congress 2018 – Moving lung transplantation forward Year: 2018 Risk stratification in patients with pulmonary arterial hypertension (PAH) and candidates for lung or heart-lung transplantation Source: Virtual Congress 2021 – All about pulmonary arterial hypertension Year: 2021 Optimising pharmacotherapy in patients with pulmonary arterial hypertension and comorbidities, including lung diseases and heart failure: benefits without harm? Source: International Congress 2018 – Integrated care for patients with pulmonary vascular disease, lung diseases and heart failure Year: 2018 New antifibrotic drugs: will interstitial diseases patients still need lung transplantation? Source: Virtual Congress 2020 – Lung transplantation in the era of new drugs Year: 2020 The effect of pulmonary hypertension on aerobic exercise capacity in lung transplant candidates with advanced COPD Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Update on current treatment options of pulmonary hypertension Source: Annual Congress 2006 - Pulmonary hypertension at the crossroads of science and clinical medicine Year: 2006 Advanced pulmonary arterial hypertension: mechanical support and lung transplantation Source: Eur Respir Rev, 26 (146) 170089; 10.1183/16000617.0089-2017 Year: 2017 PAH-specific therapies improve survival in patients with pulmonary arterial hypertension associated with connective tissue diseases: A Russian single centre experience Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Lung transplantation for pulmonary arterial hypertension Source: International Congress 2015 – Lung transplantation in the year 2015: current indications and results Year: 2015 Benefit of pulmonary rehabilitation in candidates for lung transplantation Source: Annual Congress 2011 - Improving outcomes after lung transplantation Year: 2011 Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options Source: Eur Respir Rev 2009; 18: 24-28 Year: 2009